Genprex, Inc. Stock-Based Compensation
Genprex, Inc. (GNPX) reported Stock-Based Compensation of $184.20 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2025-05-12
- Genprex, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $184.20K, a 64.30% decline year-over-year.
- Genprex, Inc. share-based payment arrangement, noncash expense for the quarter ending 2024-12-31 was $302.84K, a 70.88% decline year-over-year.
- Genprex, Inc. share-based payment arrangement, noncash expense for the quarter ending 2024-09-30 was $420.23K, a 71.80% decline year-over-year.
- Genprex, Inc. share-based payment arrangement, noncash expense for the quarter ending 2024-06-30 was $2.06M, a 33.49% increase year-over-year.
- Genprex, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $3.30M, a 38.93% decline from fiscal 2023.
- Genprex, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $5.41M, a 14.30% increase from fiscal 2022.
- Genprex, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $4.73M, a 11.51% decline from fiscal 2021.
- Genprex, Inc. share-based payment arrangement, noncash expense for fiscal 2021 was $5.35M, a 25.94% increase from fiscal 2020.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | $184.20K 10-Q · filed 2025-05-12 | $487.04K derived: sum of 2 quarters · filed 2025-05-12 | $907.26K derived: sum of 3 quarters · filed 2025-05-12 | $2.97M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2024-12-31 | $302.84K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $723.06K derived: sum of 2 quarters · filed 2025-04-01 | $2.79M derived: sum of 3 quarters · filed 2025-04-01 | $3.30M 10-K · filed 2025-04-01 | ||||
| 2024-09-30 | $420.23K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $2.48M derived: sum of 2 quarters · filed 2024-11-13 | $3.00M 10-Q · filed 2024-11-13 | $4.04M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2024-06-30 | $2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $2.58M 10-Q · filed 2024-08-09 | $3.62M derived: sum of 3 quarters · filed 2025-05-12 | $5.11M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2024-03-31 | $515.97K 10-Q · filed 2025-05-12 | $1.56M derived: sum of 2 quarters · filed 2025-05-12 | $3.05M derived: sum of 3 quarters · filed 2025-05-12 | $4.59M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $2.53M derived: sum of 2 quarters · filed 2025-04-01 | $4.08M derived: sum of 3 quarters · filed 2025-04-01 | $5.41M 10-K · filed 2025-04-01 | ||||
| 2023-09-30 | $1.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $3.04M derived: sum of 2 quarters · filed 2024-11-13 | $4.37M 10-Q · filed 2024-11-13 | $4.37M 10-Q · filed 2023-11-14 | $5.67M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $2.88M 10-Q · filed 2024-08-09 | $4.18M derived: sum of 3 quarters · filed 2024-08-09 | $5.40M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | $1.33M 10-Q · filed 2024-05-15 | $2.64M derived: sum of 2 quarters · filed 2024-05-15 | $3.86M derived: sum of 3 quarters · filed 2024-05-15 | $5.01M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.52M derived: sum of 2 quarters · filed 2024-04-01 | $3.67M derived: sum of 3 quarters · filed 2024-04-01 | $4.73M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $2.37M derived: sum of 2 quarters · filed 2023-11-14 | $3.43M 10-Q · filed 2023-11-14 | $3.18M 10-Q · filed 2022-11-14 | $6.29M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $1.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $2.21M 10-Q · filed 2023-08-21 | $2.03M 10-Q · filed 2022-08-12 | $5.07M derived: sum of 3 quarters · filed 2023-08-21 | $5.75M derived: sum of 4 quarters · filed 2023-08-21 | |||
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-22 | $1.47M 10-Q · filed 2022-05-13 | $3.92M derived: sum of 2 quarters · filed 2023-05-22 | $4.60M derived: sum of 3 quarters · filed 2023-05-22 | $5.73M derived: sum of 4 quarters · filed 2023-05-22 | |||
| 2021-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.54M derived: sum of 2 quarters · filed 2023-03-31 | $4.68M derived: sum of 3 quarters · filed 2023-03-31 | $5.35M 10-K · filed 2023-03-31 | $4.28M 10-K · filed 2022-03-30 | |||
| 2021-09-30 | $675.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.81M derived: sum of 2 quarters · filed 2022-11-14 | $2.48M 10-Q · filed 2022-11-14 | $3.16M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $1.81M 10-Q · filed 2022-08-12 | $2.48M derived: sum of 3 quarters · filed 2022-08-12 | $2.93M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $671.74K 10-Q · filed 2022-05-13 | $1.35M derived: sum of 2 quarters · filed 2022-05-13 | $1.79M derived: sum of 3 quarters · filed 2022-05-13 | $4.16M derived: sum of 4 quarters · filed 2022-05-13 | ||||
| 2020-12-31 | $673.75K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $1.12M derived: sum of 2 quarters · filed 2022-03-30 | $3.49M derived: sum of 3 quarters · filed 2022-03-30 | $4.25M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $447.82K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $2.82M derived: sum of 2 quarters · filed 2021-11-15 | $3.57M 10-Q · filed 2021-11-15 | $4.22M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $3.12M 10-Q · filed 2021-08-13 | $3.77M derived: sum of 3 quarters · filed 2021-08-13 | $4.36M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $753.99K 10-Q · filed 2021-05-17 | $1.40M derived: sum of 2 quarters · filed 2021-05-17 | $1.99M derived: sum of 3 quarters · filed 2021-05-17 | $3.76M derived: sum of 4 quarters · filed 2021-05-17 | ||||
| 2019-12-31 | $650.22K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $1.23M derived: sum of 2 quarters · filed 2021-03-26 | $3.01M derived: sum of 3 quarters · filed 2021-03-26 | $3.53M 10-K · filed 2021-03-26 | ||||
| 2019-09-30 | $581.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $2.36M derived: sum of 2 quarters · filed 2020-11-12 | $2.88M 10-Q · filed 2020-11-12 | $4.49M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $1.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $2.30M 10-Q · filed 2020-08-11 | $3.91M derived: sum of 3 quarters · filed 2020-08-11 | $4.21M derived: sum of 4 quarters · filed 2020-08-11 | ||||
| 2019-03-31 | $523.02K 10-Q · filed 2020-05-14 | $2.14M derived: sum of 2 quarters · filed 2020-05-14 | $2.43M derived: sum of 3 quarters · filed 2020-05-14 | $5.73M derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $1.91M derived: sum of 2 quarters · filed 2020-03-30 | $5.21M derived: sum of 3 quarters · filed 2020-03-30 | $5.44M 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | $294.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $3.60M derived: sum of 2 quarters · filed 2019-11-14 | $3.82M 10-Q · filed 2019-11-14 | $4.05M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $3.30M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2019-08-13 | $3.53M 10-Q · filed 2019-08-13 | $3.75M derived: sum of 3 quarters · filed 2019-08-13 | $3.97M derived: sum of 4 quarters · filed 2019-08-13 | ||||
| 2018-03-31 | $223.51K 10-Q/A · filed 2019-05-20 | $447.08K derived: sum of 2 quarters · filed 2019-05-20 | $670.71K derived: sum of 3 quarters · filed 2019-05-20 | $1.31M derived: sum of 4 quarters · filed 2019-05-20 | ||||
| 2017-12-31 | $223.56K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $447.20K derived: sum of 2 quarters · filed 2019-04-01 | $1.09M derived: sum of 3 quarters · filed 2019-04-01 | $1.32M 10-K · filed 2019-04-01 | ||||
| 2017-09-30 | $223.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $866.88K derived: sum of 2 quarters · filed 2018-11-14 | $1.10M 10-Q · filed 2018-11-14 | $1.44M derived: sum of 4 quarters · filed 2018-11-14 | ||||
| 2017-06-30 | $643.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $876.70K 10-Q · filed 2018-08-14 | $1.22M derived: sum of 3 quarters · filed 2018-08-14 | |||||
| 2017-03-31 | $233.45K 10-Q · filed 2018-05-15 | $574.01K derived: sum of 2 quarters · filed 2018-05-15 | ||||||
| 2016-12-31 | $340.56K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-17 | $2.66M 10-K · filed 2018-04-17 | $136.81K 10-Q · filed 2017-12-05 | |||||
| 2016-09-30 | $2.32M 10-Q · filed 2017-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |